Assessed for eligibility (n= 241)

- Excluded (n= 158)
  - Not meeting inclusion criteria (n= 99)
  - Declined to participate (n= 35)
  - Other reasons (n= 24)

Randomized (n= 83 [158]*)

### Enrollment

- ILMA
  - Allocated to intervention (n= 26)
    - Received allocated intervention (n= 26 [45]*)
    - Did not receive allocated intervention (n= 0)

- ILMA + non-silver dressing
  - Allocated to intervention (n= 26)
    - Received allocated intervention (n= 26 [53]*)
    - Did not receive allocated intervention (n= 0)

- ILMA + silver dressing
  - Allocated to intervention (n= 31)
    - Received allocated intervention (n= 31 [60]*)
    - Did not receive allocated intervention (n= 0)

### Allocation

### Follow-Up

- ILMA
  - Lost to follow-up (give reasons)
    - Moving to another place (n= 1)
  - Discontinued intervention (give reasons) (n=2)
    - Adverse events (2)

- ILMA + non-silver dressing
  - Lost to follow-up (give reasons) (n= 0)
  - Discontinued intervention (give reasons) (n=5)
    - Adverse events (1)
    - Inadequate efficacy (3)
    - Protocol deviation (1)

- ILMA + silver dressing
  - Lost to follow-up (give reasons)
    - Moving to another place (n= 1)
  - Discontinued intervention (give reasons) (n=1)
    - Inadequate efficacy (1)

### Analysis

- ILMA
  - Analysed (n= 23[40]*)
    - Excluded from analysis (give reasons) (n= 0)

- ILMA + non-silver dressing
  - Analysed (n= 21[45]*)
    - Excluded from analysis (give reasons) (n= 0)

- ILMA + silver dressing
  - Analysed (n= 29[55]*)
    - Excluded from analysis (give reasons) (n= 0)

*Number of the lesions. †ILMA=Intralesional meglumine antimoniate.